Published in Health Serv Res on February 01, 1994
APACHE II: a severity of disease classification system. Crit Care Med (1985) 69.83
DRG creep: a new hospital-acquired disease. N Engl J Med (1981) 4.10
Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet (1989) 3.51
The misinformation era: the fall of the medical record. Ann Intern Med (1989) 3.07
Staging of disease. A case-mix measurement. JAMA (1984) 2.89
The care of elderly patients with hip fracture. Changes since implementation of the prospective payment system. N Engl J Med (1988) 2.67
Physician and coding errors in patient records. JAMA (1985) 2.63
MEDISGRPS: a clinically based approach to classifying hospital patients at admission. Inquiry (1985) 2.59
A clinical assessment of MedisGroups. JAMA (1988) 2.50
The effect of prospective payment on Medicare expenditures. N Engl J Med (1989) 2.45
Medicare case-mix index increase. Health Care Financ Rev (1986) 2.20
Measuring severity of illness: homogeneous case mix groups. Med Care (1983) 1.99
Variation among physicians in use of laboratory tests. II. Relation to clinical productivity and outcomes of care. Med Care (1977) 1.87
The Severity of Illness Index as a severity adjustment to diagnosis-related groups. Health Care Financ Rev (1984) 1.84
Refining case-mix adjustment. The research evidence. N Engl J Med (1987) 1.48
The measurement of hospital case mix. Med Care (1982) 1.41
Severity of illness within DRGs. Homogeneity study. Med Care (1986) 1.30
Individual outcome prediction models for intensive care units. Lancet (1989) 1.22
DRG reimbursement for trauma: the demise of the trauma center (the use of ISS grouping as an early predictor of total hospital cost). J Trauma (1988) 1.21
Hospital case mix: its definition, measurement and use: Part I. The conceptual framework. Med Care Rev (1982) 1.20
A hard look at cost containment. N Engl J Med (1987) 1.03
Severity of Illness Index and the Adverse Patient Occurrence Index. A reliability study and policy implications. Med Care (1987) 1.02
Health policy report: the new era of prospective payment for hospitals. N Engl J Med (1982) 0.94
Reliability and validity of the Severity of Illness Index. Med Care (1986) 0.94
The Computerized Severity Index. A new tool for case-mix management. J Med Syst (1986) 0.89
Case mix measures: DRGs and alternatives. Annu Rev Public Health (1988) 0.78
Spectinomycin and resistant Neisseria gonorrhoeae. N Engl J Med (1988) 0.77
Improving the homogeneity of diagnosis-related groups (DRGs) by using clinical laboratory, demographic, and discharge data. Am J Public Health (1989) 0.77
The possible impact of DRGs on nutritional status of patients having surgery for cancer of the head and neck. JAMA (1988) 0.77
Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm (1981) 6.53
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet (1982) 6.06
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther (1979) 5.13
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys (2000) 5.06
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm (1977) 4.22
Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm (1992) 3.97
Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn (2001) 3.90
The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm (1993) 3.66
Estimating population kinetics. Crit Rev Biomed Eng (1982) 3.42
Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke (2001) 3.17
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm (1980) 2.90
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
Preventable drug reactions--causes and cures. N Engl J Med (1971) 2.68
The usefulness of preoperative laboratory screening. JAMA (1985) 2.55
Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys (1993) 2.55
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Forecasting individual pharmacokinetics. Clin Pharmacol Ther (1979) 2.41
Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS (2000) 2.37
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Cyclic 3',5'-adenosine monophosphate in the human lukocyte: synthesis, degradation, andeffects n neutrophil candidacidal activity. J Clin Invest (1971) 2.35
Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci (1982) 2.34
Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. Am Rev Respir Dis (1978) 2.28
A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm (1996) 2.28
Kinetics of pharmacologic response. Pharmacol Ther (1982) 2.21
Use of commercial record linkage software and vital statistics to identify patient deaths. J Am Med Inform Assoc (1997) 2.14
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med (1973) 2.11
Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis (1989) 2.09
Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther (1976) 2.08
Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. Ann Intern Med (1975) 2.04
Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm (1994) 2.04
Adenyl cyclase in human leukocytes: evidence for activation by separate beta adrenergic and prostaglandin receptors. J Pharmacol Exp Ther (1971) 2.02
Hemolytic plaque formation by leukocytes in vitro. Control by vasoactive hormones. J Clin Invest (1974) 1.98
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm (1981) 1.88
Obstacles and approaches to clinical database research: experience at the University of California, San Francisco. Proc Annu Symp Comput Appl Med Care (1994) 1.78
Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res (1972) 1.74
A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J Pharmacokinet Biopharm (1995) 1.73
The Stanford Health Information Network for Education: integrated information for decision making and learning. Proc AMIA Annu Fall Symp (1997) 1.71
Regulation of antibody response by cells expressing histamine receptors. J Exp Med (1972) 1.70
A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther (1992) 1.67
Contribution of kinins to endotoxin shock in unanesthetized Rhesus monkeys. Circ Res (1968) 1.66
Normal distribution of cardiac output in the unanesthetized, restrined rhesus monkey. J Appl Physiol (1968) 1.65
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm (1983) 1.62
The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev (1984) 1.61
Quantitative analysis of the disopyramide concentration-effect relationship. Br J Clin Pharmacol (1980) 1.58
Clinical investigators as critical determinants in pharmaceutical innovation. Nat Med (1997) 1.57
Analysis of information needs of users of the Stanford Health Information Network for Education. Proc AMIA Symp (1999) 1.50
Organization of Ripening and Ethylene Regulatory Regions in a Fruit-Specific Promoter from Tomato (Lycopersicon esculentum). Plant Physiol (1992) 1.49
Receptors for histamine can be detected on the surface of selected leukocytes. Science (1972) 1.46
Comparison of intracervical, intrauterine, and intratubal techniques for donor insemination. Fertil Steril (1993) 1.45
Computer-assisted digoxin therapy. N Engl J Med (1973) 1.43
Population dose versus response of betaxolol and atenolol: a comparison of potency and variability. Clin Pharmacol Ther (1991) 1.43
Bacterial aggregating activity in human saliva: comparisons of bacterial species and strains. Infect Immun (1981) 1.42
Estimating bioavailability when clearance varies with time. Clin Pharmacol Ther (1994) 1.42
Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS (1998) 1.42
Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med (1980) 1.40
Agonist-specific refractoriness induced by isoproterenol. Studies with mutant cells. J Biol Chem (1976) 1.39
Specific leukocyte receptors for small endogenous hormones. Detection by cell binding to insolubilized hormone preparations. J Clin Invest (1973) 1.39
Analysis of pharmacokinetic data using parametric models--1: Regression models. J Pharmacokinet Biopharm (1984) 1.38
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Plasma kinins and cortisol: a possible explanation of the anti-inflammatory action of cortisol. Science (1966) 1.37
Three new residual error models for population PK/PD analyses. J Pharmacokinet Biopharm (1995) 1.37
An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst (1985) 1.37
The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies. Arthritis Rheum (1967) 1.36
Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm (1985) 1.36
Potassium efflux and accumulation in heart muscle. Evidence from K +/- electrode experiments. Biophys J (1976) 1.35
Histamine-induced suppressor factor (HSF): further studies on the nature of the stimulus and the cell which produces it. Cell Immunol (1979) 1.33
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother (1999) 1.32
The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm (1977) 1.31
Can postmarketing surveillance help to effect optimal drug therapy? JAMA (1979) 1.27
Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther (1986) 1.26
Pharmacokinetic and pharmacodynamic modeling in vivo. Crit Rev Bioeng (1981) 1.26
Skillful mixing. Health Visit (1994) 1.25
Characterization of the human blood lymphocytes that produce a histamine-induced suppressor factor (HSF). Cell Immunol (1980) 1.23
Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med (1986) 1.23
Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci U S A (1991) 1.22
A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm (1999) 1.22
Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet (1985) 1.20
Conjugates of catecholamines. 1. N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. J Med Chem (1983) 1.20
Kinins: possible mediators of neonatal circulatory changes in man. J Clin Invest (1968) 1.19
Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors. Am J Med (1965) 1.19
Combining physiologic models and symbolic methods to interpret time-varying patient data. Methods Inf Med (1991) 1.19
The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. Br J Clin Pharmacol (1981) 1.19
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res (1987) 1.19
Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol (1989) 1.18
Disposition kinetics of lidocaine in normal subjects. Ann N Y Acad Sci (1971) 1.16
K+ fluctuations in the extracellular spaces of cardiac muscle. Evidence from the voltage clamp and extracellular K+ - selective microelectrodes. Circ Res (1982) 1.16
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res (1988) 1.16
Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin. Eur J Biochem (1981) 1.15
The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clin Radiol (1983) 1.15
Post-marketing studies of drug efficacy: why? Am J Med (1985) 1.14
Developmental changes in constriction of the ductus arteriosus: responses to oxygen and vasoactive agents in the isolated ductus arteriosus of the fetal lamb. Pediatr Res (1972) 1.14
Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst (1992) 1.14
A Markov mixed effect regression model for drug compliance. Stat Med (1998) 1.13
The clinician's approach to drug interactions. Calif Med (1968) 1.13
Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys (1996) 1.13